Title:
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors View
Indication:
Solid Tumors
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: Ib
Title:
Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View
Indication:
Epithelial Carcinomas
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Title:
A Phase I, Multi-Center, Open-Label, Treatment Duration Increment, Expansion, Safety, and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma View
Indication:
Basal Cell Carcinoma
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Title:
An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplant View
Indication:
Graft-Versus-Host-Disease
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Title:
A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma View
Indication:
Renal Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Title:
Neoadjuvant Phase II Study of Pembrolizumab and Carboplatin plus Docetaxel in Triple Negative Breast Cancer (NeoPACT) View
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Title:
A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma View
Indication:
Melanoma
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma View
Indication:
Squamous Cell Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Cemiplimab Survivorship Epidemiology (CASE) Study View
Indication:
Squamous Cell Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: IV
Title:
A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy View
Indication:
Liver Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Blood Monitoring of Oral Anticancer Drugs in Patients Undergoing Treatment for Cancer or to Prevent Cancer Recurrence View
Indication:
Miscellaneous
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Title:
A Multicenter Phase 2, Open Label Study of Intratumoral Tavo Plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment (PISCES) View
Indication:
Melanoma
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
A phase 2, multicenter, single-arm study of retreatment with brentuximab vedotin in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL) or CD30-expressing peripheral T cell lymphoma (PTCL) View
Indication:
Lymphomas
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure View
Indication:
Lung Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Biliary Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph 3 NUC-1031+Cis vs Gem/Cis la/mBTC View
Description: A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer (NuTide:121)
Indication:
Biliary Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph 3 NUC-1031+Cis vs Gem/Cis la/mBTC View
Description: A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer (NuTide:121)
Indication:
Biliary Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Bladder Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
Biomarker Advcd Uro Cncer and FGFR Aber View
Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)
Indication:
Bladder Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: IV
Title:
STAR PH 2 ASG-22CE Urothelial Cancer View
Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)
Indication:
Bladder Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I/II
Title:
Ph1 SGN-LIV1A Metastatic BC View
Description: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer (SGNLVA-001)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph2 alpelisib+fulves/letrozole HR+ HER2- View
Description: BYLieve: A phase II, multicenter, open-label, three-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant,hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after prior treatments (CBYL719X2402)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
Ph3 SYD985 HER2+ unresect adv/mBC View
Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
FLEX Registry: Evaluate New Gene Express View
Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Title:
Ph3 Pembro HR+/HER2- BC View
Description: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph 1b2 LIV1A+Pembro 1L mTNBC View
Description: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I/II
Title:
Ph 1/1b TNBC, Ovarian View
Description: (AB928CSP0002) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
CONTESSA2: Ph2 HER2- HR+ BC View
Description: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane(ODO-TE-B201)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
Ph3 IMMU-132 HR+, HER2- mBC View
Description: Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens (IMMU-132-09)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph1/2 CDK7 inhibitor HR+ BC View
Description: A Phase 1/2 Study of CT7001 in Combination with Fulvestrant in Patients with Metastatic or Locally Advanced Hormone-Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (CT7001_001)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I/II
Title:
CONTESSA TRIO: Tes + PD-L1 HER2- LA/MBC View
Description: A Multicenter, Phase 2 Study of Tesetaxel plus Three Different PD-(L)1 Inhibitors in Patients with Triple-Negative, Locally Advanced orMetastatic Breast Cancer and Tesetaxel Monotherapy in Elderly Patients with HER2 Negative, Locally Advanced or Metastatic Breast Cancer (ODO-TE-B202)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
Ph 3 Tuca/Placbo + T-DM1 HER2+ View
Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph 3 Ribo w/ endo ther HR+ HER2- BC View
Description: CLEE011O12301C (TRIO033): A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE).
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
PhI/II PK Multi Tumor SubQ Nivo Mono View
Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)
Indication:
Colon Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I/II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Colon Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
Ph3 TSR-042+car-pac vs plac+car-pac endo View
Description: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB (TSR-042) PLUS CARBOPLATIN-PACLITAXEL VERSUS PLACEBO PLUS CARBOPLATIN-PACLITAXEL IN PATIENTS WITH RECURRENT OR PRIMARY ADVANCED ENDOMETRIAL CANCER (RUBY) (4010-03-001 / ENGOT EN-6 / GOG-3031)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
STAR Ph3 Sinti vs Placebo ESCC View
Description: A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301
Indication:
Esophageal Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Essential Thrombocythemia
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Essential Thrombocythemia
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph3 TSR-042, Niraparib Ovarian FIRST View
Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph3 2L DCC-2618 vs sunitinib GIST View
Description: (DCC-2618-03-002) A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib
Indication:
GI Stromal Tumor (GIST)
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph3 Itacitinib GVHD (GRAVITAS309) View
Description: INCB 39110-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)
Indication:
Graft vs Host Disease
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph3 GC4419 Oral Mucositis H&N View
Description: ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419)- Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer (GTI-4419-301)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph3 Itacitinib GVHD (GRAVITAS309) View
Description: INCB 39110-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)
Indication:
Hematologic
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph3 R/R CLL/SLL View
Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)
Indication:
Leukemia
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph2 BGB-3111 Ibrut intolerant CLL/SLL View
Description: A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Leukemia
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
PhI/II PK Multi Tumor SubQ Nivo Mono View
Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)
Indication:
Liver Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I/II
Title:
Atezo Rollover for GNE & Roche View
Description: BO39633 (IMbrella A), An open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in A Genentech- and/or F.Hoffman-La Roche Ltd. sponsored Atezolizumab Study
Indication:
Lung Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II/III
Title:
PhI/II PK Multi Tumor SubQ Nivo Mono View
Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)
Indication:
Lung Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I/II
Title:
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View
Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Indication:
Lung Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph 1/1b Immunotherapy Combo in NSCLC View
Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer
Indication:
Lung Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph 3 Sit+Nivo vs. Docetaxel NSCLC View
Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)
Indication:
Lung Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Lung Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
PH3 AMG 510 vs Doce a/mNSCLC View
Description: 20190009: A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects with Mutated KRAS p.G12C
Indication:
Lung Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
PH3 AMG 510 vs Doce a/mNSCLC View
Description: 20190009: A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects with Mutated KRAS p.G12C
Indication:
Lung Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View
Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)
Indication:
Lung Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View
Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)
Indication:
Lung Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
STAR KEAP1/NRF2 NSCLC View
Description: CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Indication:
Lung Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
STAR KEAP1/NRF2 NSCLC View
Description: CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Indication:
Lung Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
STAR BV in older pts w/1L cHL or PTCL View
Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
Indication:
Lymphomas
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
Ph1 INCB050465 B-Cell (CITADEL-112) View
Description: INCB 50465-112: A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
Indication:
Lymphomas
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph3 R/R CLL/SLL View
Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)
Indication:
Lymphomas
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph2 BGB-3111 Ibrut intolerant CLL/SLL View
Description: A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Lymphomas
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
PhI/II PK Multi Tumor SubQ Nivo Mono View
Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)
Indication:
Melanoma
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I/II
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Myelofibrosis
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Myelofibrosis
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph3 R/R MM (DREAMM 3) View
Description: 207495: A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM3)
Indication:
Myelomas
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
PH3 Dara/Len vs Len NDMM View
Description: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)
Indication:
Myelomas
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph3 TSR-042, Niraparib Ovarian FIRST View
Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Indication:
Ovarian Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph 1/1b TNBC, Ovarian View
Description: (AB928CSP0002) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies
Indication:
Ovarian Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
TTFlds cncmnt w/ PTX recurrent ovn cnr View
Description: ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study ofTumor Treating Fields (TTFields, 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer
Indication:
Ovarian Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
PANOVA-3: 1L Gemcit + nab-pac pancreatic View
Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
Ph3 TSR-042, Niraparib Ovarian FIRST View
Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
STAR Ph3 Nirap+Abirat+Pred mCRPC View
Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
STAR Ph3 Nirap+Abirat+Pred mCRPC View
Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
STAR Abirat+pred +/- abemaciclib mCRPC View
Description: CYCLONE 2: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)
Indication:
Prostate Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
STAR PH1b/2 Nirap Combo Tx for mCRPC View
Description: A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (PCR2002 Quest) (64091742PCR2002)
Indication:
Prostate Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I/II
Title:
STAR PH1b/2 Nirap Combo Tx for mCRPC View
Description: A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (PCR2002 Quest) (64091742PCR2002)
Indication:
Prostate Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I/II
Title:
PhI/II PK Multi Tumor SubQ Nivo Mono View
Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)
Indication:
Renal Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I/II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Solid Tumors
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
STAR Ph2 Pemigatinib Solids FGFR View
Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Indication:
Solid Tumors
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
STAR Ph2 Pemigatinib Solids FGFR View
Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Indication:
Solid Tumors
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
STAR Ph2 Erdafitinib FGFR Solid Tumors View
Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)
Indication:
Solid Tumors
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
STAR Ph2 Erdafitinib FGFR Solid Tumors View
Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)
Indication:
Solid Tumors
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
STAR Ph3 FGFR erdafitinib urothelial View
Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
STAR Ph3 FGFR erdafitinib urothelial View
Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Biomarker Advcd Uro Cncer and FGFR Aber View
Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: IV
Title:
STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View
Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View
Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
STAR PH 2 ASG-22CE Urothelial Cancer View
Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I/II